American Cancer Society adds Shield blood test to colorectal cancer screening guidelines (nbcnews.com)

• ACS adds Shield blood test as screening option for those declining colonoscopy or stool testing.
• Shield is 83% sensitive for colorectal cancer but poor for early-stage and precancerous polyps.
• Test costs $895 out-of-pocket; insurance coverage not guaranteed without USPSTF recommendation.

"The American Cancer Society updated its colorectal cancer screening guidelines to include the Shield blood test (Guardant Health, FDA-approved 2024) for individuals who decline or cannot undergo colonoscopy or stool tests. The test detects tumor DNA with 83% sensitivity but misses precancerous polyps and early-stage cancers. It does not replace colonoscopy; positive results require follow-up. The test costs $895 out-of-pocket and insurance coverage is not yet mandated."